American Journal of Clinical Medicine Research
ISSN (Print): 2328-4005 ISSN (Online): 2328-403X Website: Editor-in-chief: Dario Galante
Open Access
Journal Browser
American Journal of Clinical Medicine Research. 2015, 3(1), 14-17
DOI: 10.12691/ajcmr-3-1-3
Open AccessArticle

Elective Cryopreservation of all 2PN Oocytes after in-vitro Maturation: a Prospective, Clinical Pilot Study

Abu Marar E1, , Schultze-Mosgau A1, Depenbusch M1, von Otte S2, Schöpper B1 and Griesinger G1

1Department of Gynecological Endocrinology and Reproductive Medicine, University Hospital of Schleswig-Holstein, Campus Lübeck, Lübeck, Germany

2Fertility Center, Kiel, Germany

Pub. Date: March 16, 2015

Cite this paper:
Abu Marar E, Schultze-Mosgau A, Depenbusch M, von Otte S, Schöpper B and Griesinger G. Elective Cryopreservation of all 2PN Oocytes after in-vitro Maturation: a Prospective, Clinical Pilot Study. American Journal of Clinical Medicine Research. 2015; 3(1):14-17. doi: 10.12691/ajcmr-3-1-3


Purpose: To evaluate the effectiveness of temporally splitting in-vitro maturation and embryo transfer by elective cryopreserving of all 2PN oocytes after in–vitro maturation (IVM). Methods: This one armed clinical cohort study was prospectively performed. Twenty eight patients fulfilled the inclusion criteria after AFC assessment by transvaginal sonography. Patients were retrospectively divided into (primed) group which received a low dose of gonadotropin stimulation, and (non-primed) group which received no medication. IVM in combination with cryopreservation by vitrification of all 2PN oocytes was investigated for all included patients. Results: Mean number of cumulus-oocyte complex (COC) was found to be 9 ± 8.4 and the average number of matured oocytes was 4.1 ± 4.8. After vitrification and thawing, the overall survival rate was 92.9%. The overall clinical pregnancy rate per WHAT was 17.9%. The cumulative clinical and ongoing pregnancy rate per patient with at least one embryo transfer (ET) performed was 23.8% and 12.1-41.6% for 95% confidence interval (CI). No differences was found for in outcome between primed and non-primed patients in positive hCG results. Conclusions: The addition of electively cryopreservation by vitrification of all 2PN stage embryos to IVM technique applied for high AFC in patients undergoing IVF treatment in both primed and natural cycles results in an acceptable chance of ongoing pregnancy.

cryopreservation PCO IVM

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit


[1]  Hardy K, Wright CS, Franks S, Winston RM. In vitro maturation of oocytes. Br Med Bull. 2000; 56 (3): 588-602.
[2]  Wiser A, Shehata F, Holzer H, Hyman JH, Shalom-Paz E, Son WY, Tulandi T. Effect of high LH/FSH ratio on women with polycystic ovary syndrome undergoing in vitro maturation treatment. J Reprod Med. 2013; 58 (5-6): 219-23.
[3]  De Vos M, Ortega Hrepich C, Albuz FK, Guzman L Polyzos NP, Smitz J,Devroey P. Clinical outcome of non-hCG-primed oocyte in vitro maturation treatment in patients with polycystic ovaries and polycystic ovary syndrome. FertilSteril 2011; 96: 860-4.
[4]  Jacobs HS, Agrawal R.Complications of ovarian stimulation. Baillieres Clin Obstet Gynaecol. 1998; 4: 565-79.
[5]  Broer SL, Dólleman M, Opmeer BC, Fauser BC, Mol BW, Broekmans FJ. AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: a meta-analysis. Human Reprod Update 2011; 17 (1): 46-54.
[6]  Kwee J, Schats R, McDonnell J, ThemmenA, de Jong F, Lambalk C. Evaluation of anti-Müllerian hormone as a test for the prediction of ovarian reserve. FertilSteril 2008; 90 (3): 737-743.
[7]  Pelin O, Sezai S, Meral C, Tulay I, Onur G, and Ismail C. Serum anti-Müllerian hormone and antral follicle count as predictive markers of OHSS in ART cycles. J Assist Reprod Genet. 2011; 28 (12): 1197-1203.
[8]  Wiser A, Shalom-Paz E, Hyman JH, Sokal-Arnon T, Bantan N, Holzer H, Tulandi T. Age-related normogram for antral follicle count in women with polycystic ovary syndrome. Reprod Biomed Online. 2013; 27 (4): 414-8.
[9]  Devroey P, Polyzos NP, Blockeel C. An OHSS-Free Clinic by segmentation of IVF treatment. Human Reprod 2011; 26 (10): 2593-7.
[10]  Himabindu Y, Sriharibabu M, Gopinathan K, Satish U, Louis TF, Gopinath P. Anti-mullerian hormone and antral follicle count as predictors of ovarian response in assisted reproduction. J Hum Reprod Sci. 2013; 6 (1): 27-31.
[11]  Diedrich K, Fauser BC, Devroey P; Evian Annual Reproduction (EVAR) Workshop Group 2009. Cancer and fertility: strategies to preserve fertility. Reprod Biomed Online. 2011;22(3):232-48.
[12]  Roesner S, Von Wolff M, Eberhardt I, Beuter-Winkler P, Toth B, Strowitzki T. In vitro maturation: a five-year experience. Acta Obstet Gynecol Scand. 2012; 91 (1): 22-7.
[13]  Ronn R, Holzer HE. Oncofertility in Canada: cryopreservation and alternative options for future parenthood. Curr Oncol. 2014 Feb; 21 (1): e137-46.
[14]  Álvarez C, García-Garrido C, Taronger R, González de Merlo G. In vitro maturation, fertilization, embryo development & clinical outcome of human metaphase-I oocytes retrieved from stimulated intracytoplasmic sperm injection cycles. Indian J Med Res. 2013; 137 (2): 331-8.
[15]  Mermillod P, Oussaid B, Cognié Y. Aspects of follicular and oocyte maturation that affect the developmental potential of embryos. JReprodFertil Suppl. 1999; 54: 449-60.
[16]  Buckett WM, Chian RC, Tan SL. Human chorionic gonadotropin for in vitro oocyte maturation: does it improve the endometrium or implantation? Reprod Med. 2004; 49 (2): 93-8.
[17]  Levron J, Leibovitz O, Brengauz M, Gitman H, Yerushalmi GM, Katorza E, Gat I, Elizur SE. Cryopreservation of day 2-3 embryos by vitrification yields better outcome than slow freezing. Gynecol Endocrinol. 2014; 30 (3): 202-4.
[18]  Kuwayama M, Vajta G, Kato O, Leibo SP. Highly efficient vitrification method for cryopreservation of human oocytes. Reprod Biomed Online. 2005; 11 (3): 300-8.
[19]  Griesinger G, Weig M, Schroer A, Diedrich K, Kolibianakis EM. Mid-cycle serum levels of endogenous LH are not associated with the likelihood of pregnancy in artificial frozen-thawed embryo transfer cycles without pituitary suppression. Hum Reprod. 2007; 22 (10): 2589-93.
[20]  Al-Hasani S, Ozmen B, Koutlaki N, Schoepper B, Diedrich K, Schultze-Mosgau A.Three years of routine vitrification of human zygotes: is it still fair to advocate slow-rate freezing? Reprod Biomed Online. 2007; 14 (3): 288-93.
[21]  Kwee J, Elting ME, Schats R, McDonnell J, LambalkCB. Ovarian volume and antral follicle count for the prediction of low and hyper responders with in vitro fertilization. Reprod Biol Endocrinol. 2007; 5: 9.
[22]  Tucker MJ, Wright G, Morton PC, Massey JB. Birth after cryopreservation of immature oocytes with subsequent in vitro maturation. FertilSteril. 1998; 70 (3): 578-9.
[23]  Beyer DA, Amari F, Diedrich K, Al Hasani S. Embryo survival after vitrification of 2 PN oocytes. Middle East FertilSoc J. 2011; 16 (1): 45-49.
[24]  Son WY, Chung JT, Gidoni Y, Holzer H, Levin D, Chian RC, Tan SL. Comparison of survival rate of cleavage stage embryos produced from in vitro maturation cycles after slow freezing and after vitrification. FertilSteril. 2009; 92 (3): 956-8.
[25]  Pavone ME, Innes J, Hirshfeld-Cytron J, Kazer R, Zhang J. Comparing thaw survival, implantation and live birth rates from cryopreserved zygotes, embryos and blastocysts.J Hum Reprod Sci. 2011; 4 (1): 23-28.
[26]  Lucena E, Moreno-Ortiz H. Granulocyte colony-stimulating factor (G-CSF): a mediator in endometrial receptivity for a patient with polycystic ovary (PCO) undergoing in vitro maturation (IVM). BMJ Case Rep. 2013.
[27]  Xu J, Xu M, Bernuci MP, Fisher TE, Shea LD, Woodruff TK, Zelinski MB, Stouffer RL. Primate follicular development and oocyte maturation in vitro. Adv Exp Med Biol. 2013; 761: 43-67.
[28]  Ortega-Hrepich C, Stoop D, Guzmán L, Van Landuyt L, Tournaye H, Smitz J, De Vos M. A ‘‘freeze-all’’ embryo strategy after in vitro maturation: a novel approach in women with polycystic ovary syndrome? FertilSteril. 2013; 100 (4): 1002-7.